Payment overview · 2025
General Payments
$87.23
5 reported records · 3 companies
Healthcare provider profile · identity verified
Viola Jones, AG-NP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · ROANOKE, VA · NPI 1912369489
Verified facts
What the public records show
CMS Open Payments records show Viola Jones, AG-NP-BC received $87.23 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 54.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.44 | 54.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.62 | 24.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.17 | 20.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $87.23 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $47.44 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $47.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 304 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 64 |
| Furosemide | Furosemide | 263 | 86 |
| Gabapentin | Gabapentin | 237 | 53 |
| Prednisone | Prednisone | 188 | 107 |
| Carvedilol | Carvedilol | 186 | 36 |
| Eliquis | Apixaban | 149 | 27 |
| Losartan Potassium | Losartan Potassium | 148 | 40 |
| Potassium Chloride | Potassium Chloride | 145 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 36 |
| Omeprazole | Omeprazole | 136 | 35 |
| Mounjaro | Tirzepatide | 132 | 22 |
| Trulicity | Dulaglutide | 130 | 19 |
| Ozempic | Semaglutide | 116 | 21 |
| Montelukast Sodium | Montelukast Sodium | 102 | 22 |
| Lisinopril | Lisinopril | 101 | 26 |
| Allopurinol | Allopurinol | 100 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 100 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 27 |
| Mirtazapine | Mirtazapine | 77 | 29 |
| Levetiracetam | Levetiracetam | 76 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 27 |
| Tramadol Hcl | Tramadol Hcl | 75 | 24 |
| Sertraline Hcl | Sertraline Hcl | 71 | 14 |
| Azithromycin | Azithromycin | 69 | 46 |
| Trazodone Hcl | Trazodone Hcl | 66 | 19 |
| Nystatin | Nystatin | 65 | 32 |
| Warfarin Sodium | Warfarin Sodium | 65 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 14 |
| Donepezil Hcl | Donepezil Hcl | 62 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 15 |
| Metformin Hcl | Metformin Hcl | 60 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 15 |
| Lorazepam | Lorazepam | 59 | 22 |
| Lactulose | Lactulose | 54 | 17 |
| Torsemide | Torsemide | 54 | 12 |
| Glimepiride | Glimepiride | 53 | 15 |
| Methylprednisolone | Methylprednisolone | 53 | 42 |
| Linzess | Linaclotide | 49 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 49 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Levofloxacin | Levofloxacin | 48 | 36 |
| Pregabalin | Pregabalin | 47 | 11 |
| Famotidine | Famotidine | 46 | 17 |
| Fluconazole | Fluconazole | 45 | 31 |
| Latanoprost | Latanoprost | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 20 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 14 |
| Simvastatin | Simvastatin | 35 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 20 |
| Budesonide | Budesonide | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 15 |
| Memantine Hcl | Memantine Hcl | 32 | 12 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 21 |
| Meloxicam | Meloxicam | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Phenytoin | Phenytoin | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 22 |
| Metronidazole | Metronidazole | 29 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 27 | 27 |
| Alprazolam | Alprazolam | 27 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 17 |
| Mupirocin | Mupirocin | 27 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Enulose | Lactulose | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Anastrozole | Anastrozole | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Colchicine | Colchicine | 23 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 23 |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 16 |
| Trimethoprim | Trimethoprim | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Xtampza Er | Oxycodone Myristate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $87.23 · 5 records | ABBVIE INC. | CREON, IBSRELA, LINZESS, Ozempic, Rybelsus, VIBERZI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error